Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study
Table 2
Summary of the baseline nerve conduction study and mTCNS.
Ranirestat ()
Placebo ()
values
Nerve conduction velocity (m/s)
Summed sensory NCV
146.37 ± 13.47
146.13 ± 12.75
0.940
Right sural sensory NCV
44.15 ± 4.88
45.11 ± 5.05
0.420
Left sural sensory NCV
43.81 ± 5.85
44.71 ± 4.96
0.491
Proximal median sensory NCV
57.96 ± 5.58
56.08 ± 4.68
0.132
Distal median sensory NCV
46.13 ± 8.76
44.35 ± 9.90
0.419
Median motor NCV
51.45 ± 4.30
50.47 ± 3.53
0.299
Tibial motor NCV
39.79 ± 4.44
39.76 ± 3.71
0.975
F-wave latency (ms)
Median motor MFWL
27.29 ± 2.95
28.88 ± 2.00
0.010
Tibial motor MFWL
50.98 ± 5.28
52.55 ± 4.21
0.180
mTCNS (pt)
Total score
7.6 ± 5.8
7.3 ± 4.4
0.806
Symptom domain
3.0 ± 2.7
3.1 ± 2.6
0.917
Sensory domain
4.6 ± 3.7
4.2 ± 3.0
0.647
Data are mean ± SD. values for other parameters were obtained from Student -tests. mTCNS total score is the sum of symptom domain and sensory domain scores. The symptom domain score is the sum of individual symptom scores, and the sensory domain score is the sum of individual sensory scores.
